nodes	percent_of_prediction	percent_of_DWPC	metapath
Orlistat—PLA2G4A—Epirubicin—thyroid cancer	0.539	0.899	CbGbCtD
Orlistat—CYP3A4—Vandetanib—thyroid cancer	0.0307	0.0512	CbGbCtD
Orlistat—CYP3A4—Sorafenib—thyroid cancer	0.0185	0.0309	CbGbCtD
Orlistat—CYP3A4—Doxorubicin—thyroid cancer	0.0112	0.0187	CbGbCtD
Orlistat—ABHD16A—saliva-secreting gland—thyroid cancer	0.00882	0.081	CbGeAlD
Orlistat—ABHD12—saliva-secreting gland—thyroid cancer	0.00826	0.0759	CbGeAlD
Orlistat—DAGLA—head—thyroid cancer	0.00813	0.0746	CbGeAlD
Orlistat—DAGLB—thyroid gland—thyroid cancer	0.0071	0.0652	CbGeAlD
Orlistat—FASN—saliva-secreting gland—thyroid cancer	0.00694	0.0637	CbGeAlD
Orlistat—FASN—Afatinib—Vandetanib—thyroid cancer	0.00685	1	CbGdCrCtD
Orlistat—ABHD16A—trachea—thyroid cancer	0.0068	0.0625	CbGeAlD
Orlistat—ABHD12—trachea—thyroid cancer	0.00638	0.0585	CbGeAlD
Orlistat—PLA2G7—thyroid gland—thyroid cancer	0.00574	0.0527	CbGeAlD
Orlistat—ABHD16A—thyroid gland—thyroid cancer	0.00538	0.0494	CbGeAlD
Orlistat—FASN—trachea—thyroid cancer	0.00535	0.0491	CbGeAlD
Orlistat—ABHD12—thyroid gland—thyroid cancer	0.00504	0.0463	CbGeAlD
Orlistat—PNLIP—head—thyroid cancer	0.00447	0.0411	CbGeAlD
Orlistat—DAGLB—lymph node—thyroid cancer	0.00441	0.0405	CbGeAlD
Orlistat—FASN—thyroid gland—thyroid cancer	0.00423	0.0389	CbGeAlD
Orlistat—PLA2G7—lymph node—thyroid cancer	0.00356	0.0327	CbGeAlD
Orlistat—ABHD16A—lymph node—thyroid cancer	0.00334	0.0307	CbGeAlD
Orlistat—PLA2G4A—saliva-secreting gland—thyroid cancer	0.00333	0.0306	CbGeAlD
Orlistat—ABHD12—lymph node—thyroid cancer	0.00313	0.0288	CbGeAlD
Orlistat—FASN—lymph node—thyroid cancer	0.00263	0.0241	CbGeAlD
Orlistat—PLA2G4A—trachea—thyroid cancer	0.00257	0.0236	CbGeAlD
Orlistat—PLA2G4A—thyroid gland—thyroid cancer	0.00203	0.0187	CbGeAlD
Orlistat—PLA2G4A—lymph node—thyroid cancer	0.00126	0.0116	CbGeAlD
Orlistat—Nail disorder—Doxorubicin—thyroid cancer	0.000766	0.00397	CcSEcCtD
Orlistat—Infection—Vandetanib—thyroid cancer	0.000764	0.00395	CcSEcCtD
Orlistat—Nervous system disorder—Vandetanib—thyroid cancer	0.000754	0.0039	CcSEcCtD
Orlistat—Skin disorder—Vandetanib—thyroid cancer	0.000747	0.00387	CcSEcCtD
Orlistat—Haemoglobin—Sorafenib—thyroid cancer	0.000734	0.0038	CcSEcCtD
Orlistat—Haemorrhage—Sorafenib—thyroid cancer	0.00073	0.00378	CcSEcCtD
Orlistat—Urinary tract disorder—Sorafenib—thyroid cancer	0.000721	0.00373	CcSEcCtD
Orlistat—Urethral disorder—Sorafenib—thyroid cancer	0.000715	0.0037	CcSEcCtD
Orlistat—Musculoskeletal discomfort—Vandetanib—thyroid cancer	0.0007	0.00363	CcSEcCtD
Orlistat—Insomnia—Vandetanib—thyroid cancer	0.000695	0.0036	CcSEcCtD
Orlistat—Paraesthesia—Vandetanib—thyroid cancer	0.00069	0.00357	CcSEcCtD
Orlistat—Dyspepsia—Vandetanib—thyroid cancer	0.000677	0.0035	CcSEcCtD
Orlistat—Decreased appetite—Vandetanib—thyroid cancer	0.000668	0.00346	CcSEcCtD
Orlistat—Gastrointestinal disorder—Vandetanib—thyroid cancer	0.000664	0.00344	CcSEcCtD
Orlistat—Fatigue—Vandetanib—thyroid cancer	0.000663	0.00343	CcSEcCtD
Orlistat—Immune system disorder—Sorafenib—thyroid cancer	0.000659	0.00341	CcSEcCtD
Orlistat—Mediastinal disorder—Sorafenib—thyroid cancer	0.000658	0.00341	CcSEcCtD
Orlistat—Pain—Vandetanib—thyroid cancer	0.000657	0.0034	CcSEcCtD
Orlistat—Alopecia—Sorafenib—thyroid cancer	0.000645	0.00334	CcSEcCtD
Orlistat—Blood disorder—Epirubicin—thyroid cancer	0.000643	0.00333	CcSEcCtD
Orlistat—Mental disorder—Sorafenib—thyroid cancer	0.000639	0.00331	CcSEcCtD
Orlistat—Malnutrition—Sorafenib—thyroid cancer	0.000635	0.00329	CcSEcCtD
Orlistat—Gastrointestinal pain—Vandetanib—thyroid cancer	0.000629	0.00325	CcSEcCtD
Orlistat—Dysgeusia—Sorafenib—thyroid cancer	0.000622	0.00322	CcSEcCtD
Orlistat—Amenorrhoea—Epirubicin—thyroid cancer	0.000611	0.00317	CcSEcCtD
Orlistat—Cardiovascular disorder—Epirubicin—thyroid cancer	0.000611	0.00317	CcSEcCtD
Orlistat—Muscle spasms—Sorafenib—thyroid cancer	0.000611	0.00316	CcSEcCtD
Orlistat—Abdominal pain—Vandetanib—thyroid cancer	0.000608	0.00315	CcSEcCtD
Orlistat—Body temperature increased—Vandetanib—thyroid cancer	0.000608	0.00315	CcSEcCtD
Orlistat—Blood disorder—Doxorubicin—thyroid cancer	0.000595	0.00308	CcSEcCtD
Orlistat—Rectal haemorrhage—Epirubicin—thyroid cancer	0.000595	0.00308	CcSEcCtD
Orlistat—Arthropathy—Epirubicin—thyroid cancer	0.000591	0.00306	CcSEcCtD
Orlistat—Angioedema—Sorafenib—thyroid cancer	0.000581	0.00301	CcSEcCtD
Orlistat—Amenorrhoea—Doxorubicin—thyroid cancer	0.000566	0.00293	CcSEcCtD
Orlistat—Cardiovascular disorder—Doxorubicin—thyroid cancer	0.000566	0.00293	CcSEcCtD
Orlistat—Cough—Sorafenib—thyroid cancer	0.000554	0.00287	CcSEcCtD
Orlistat—Asthenia—Vandetanib—thyroid cancer	0.000552	0.00286	CcSEcCtD
Orlistat—Rectal haemorrhage—Doxorubicin—thyroid cancer	0.00055	0.00285	CcSEcCtD
Orlistat—Arthropathy—Doxorubicin—thyroid cancer	0.000547	0.00283	CcSEcCtD
Orlistat—Pruritus—Vandetanib—thyroid cancer	0.000544	0.00282	CcSEcCtD
Orlistat—Myalgia—Sorafenib—thyroid cancer	0.000541	0.0028	CcSEcCtD
Orlistat—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—thyroid cancer	0.000537	0.00278	CcSEcCtD
Orlistat—Vaginal inflammation—Epirubicin—thyroid cancer	0.000537	0.00278	CcSEcCtD
Orlistat—Dry mouth—Sorafenib—thyroid cancer	0.000529	0.00274	CcSEcCtD
Orlistat—Eructation—Epirubicin—thyroid cancer	0.000528	0.00273	CcSEcCtD
Orlistat—Diarrhoea—Vandetanib—thyroid cancer	0.000526	0.00272	CcSEcCtD
Orlistat—Anaphylactic shock—Sorafenib—thyroid cancer	0.000519	0.00268	CcSEcCtD
Orlistat—Infection—Sorafenib—thyroid cancer	0.000515	0.00267	CcSEcCtD
Orlistat—Nervous system disorder—Sorafenib—thyroid cancer	0.000509	0.00263	CcSEcCtD
Orlistat—Dizziness—Vandetanib—thyroid cancer	0.000508	0.00263	CcSEcCtD
Orlistat—Vaginal infection—Epirubicin—thyroid cancer	0.000507	0.00263	CcSEcCtD
Orlistat—Skin disorder—Sorafenib—thyroid cancer	0.000504	0.00261	CcSEcCtD
Orlistat—Vaginal inflammation—Doxorubicin—thyroid cancer	0.000497	0.00257	CcSEcCtD
Orlistat—Cramps of lower extremities—Epirubicin—thyroid cancer	0.000493	0.00255	CcSEcCtD
Orlistat—Vomiting—Vandetanib—thyroid cancer	0.000489	0.00253	CcSEcCtD
Orlistat—Eructation—Doxorubicin—thyroid cancer	0.000488	0.00253	CcSEcCtD
Orlistat—Neoplasm—Epirubicin—thyroid cancer	0.000486	0.00251	CcSEcCtD
Orlistat—Rash—Vandetanib—thyroid cancer	0.000485	0.00251	CcSEcCtD
Orlistat—Dermatitis—Vandetanib—thyroid cancer	0.000484	0.00251	CcSEcCtD
Orlistat—Headache—Vandetanib—thyroid cancer	0.000482	0.00249	CcSEcCtD
Orlistat—Musculoskeletal discomfort—Sorafenib—thyroid cancer	0.000472	0.00245	CcSEcCtD
Orlistat—Vaginal infection—Doxorubicin—thyroid cancer	0.000469	0.00243	CcSEcCtD
Orlistat—Nausea—Vandetanib—thyroid cancer	0.000457	0.00236	CcSEcCtD
Orlistat—Cramps of lower extremities—Doxorubicin—thyroid cancer	0.000457	0.00236	CcSEcCtD
Orlistat—Dyspepsia—Sorafenib—thyroid cancer	0.000456	0.00236	CcSEcCtD
Orlistat—Decreased appetite—Sorafenib—thyroid cancer	0.000451	0.00233	CcSEcCtD
Orlistat—Neoplasm—Doxorubicin—thyroid cancer	0.000449	0.00233	CcSEcCtD
Orlistat—Diabetes mellitus—Epirubicin—thyroid cancer	0.000448	0.00232	CcSEcCtD
Orlistat—Gastrointestinal disorder—Sorafenib—thyroid cancer	0.000448	0.00232	CcSEcCtD
Orlistat—Fatigue—Sorafenib—thyroid cancer	0.000447	0.00231	CcSEcCtD
Orlistat—Pain—Sorafenib—thyroid cancer	0.000443	0.0023	CcSEcCtD
Orlistat—Eczema—Epirubicin—thyroid cancer	0.000434	0.00225	CcSEcCtD
Orlistat—Hepatic failure—Epirubicin—thyroid cancer	0.000434	0.00225	CcSEcCtD
Orlistat—Gastrointestinal pain—Sorafenib—thyroid cancer	0.000424	0.0022	CcSEcCtD
Orlistat—Increased appetite—Epirubicin—thyroid cancer	0.000415	0.00215	CcSEcCtD
Orlistat—Diabetes mellitus—Doxorubicin—thyroid cancer	0.000415	0.00215	CcSEcCtD
Orlistat—Menopausal symptoms—Epirubicin—thyroid cancer	0.000413	0.00214	CcSEcCtD
Orlistat—Urticaria—Sorafenib—thyroid cancer	0.000412	0.00213	CcSEcCtD
Orlistat—Body temperature increased—Sorafenib—thyroid cancer	0.00041	0.00212	CcSEcCtD
Orlistat—Abdominal pain—Sorafenib—thyroid cancer	0.00041	0.00212	CcSEcCtD
Orlistat—Dermatitis bullous—Epirubicin—thyroid cancer	0.000408	0.00211	CcSEcCtD
Orlistat—Eczema—Doxorubicin—thyroid cancer	0.000401	0.00208	CcSEcCtD
Orlistat—Hepatic failure—Doxorubicin—thyroid cancer	0.000401	0.00208	CcSEcCtD
Orlistat—Hypoglycaemia—Epirubicin—thyroid cancer	0.0004	0.00207	CcSEcCtD
Orlistat—Osteoarthritis—Epirubicin—thyroid cancer	0.00039	0.00202	CcSEcCtD
Orlistat—Increased appetite—Doxorubicin—thyroid cancer	0.000384	0.00199	CcSEcCtD
Orlistat—Menopausal symptoms—Doxorubicin—thyroid cancer	0.000382	0.00198	CcSEcCtD
Orlistat—Hypersensitivity—Sorafenib—thyroid cancer	0.000382	0.00198	CcSEcCtD
Orlistat—Dermatitis bullous—Doxorubicin—thyroid cancer	0.000377	0.00195	CcSEcCtD
Orlistat—Asthenia—Sorafenib—thyroid cancer	0.000372	0.00193	CcSEcCtD
Orlistat—Hypoglycaemia—Doxorubicin—thyroid cancer	0.00037	0.00191	CcSEcCtD
Orlistat—Pruritus—Sorafenib—thyroid cancer	0.000367	0.0019	CcSEcCtD
Orlistat—Osteoarthritis—Doxorubicin—thyroid cancer	0.000361	0.00187	CcSEcCtD
Orlistat—Dry skin—Epirubicin—thyroid cancer	0.000357	0.00185	CcSEcCtD
Orlistat—Abdominal pain upper—Epirubicin—thyroid cancer	0.000356	0.00184	CcSEcCtD
Orlistat—Hypokalaemia—Epirubicin—thyroid cancer	0.000355	0.00184	CcSEcCtD
Orlistat—Diarrhoea—Sorafenib—thyroid cancer	0.000355	0.00184	CcSEcCtD
Orlistat—Breast disorder—Epirubicin—thyroid cancer	0.000352	0.00182	CcSEcCtD
Orlistat—DAGLA—GPCR downstream signaling—SST—thyroid cancer	0.00035	0.00384	CbGpPWpGaD
Orlistat—DAGLB—Signaling by GPCR—PTCH1—thyroid cancer	0.000348	0.00381	CbGpPWpGaD
Orlistat—DAGLA—Signaling by GPCR—PTCH1—thyroid cancer	0.000348	0.00381	CbGpPWpGaD
Orlistat—Gastritis—Epirubicin—thyroid cancer	0.000345	0.00179	CcSEcCtD
Orlistat—DAGLB—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—thyroid cancer	0.000344	0.00377	CbGpPWpGaD
Orlistat—DAGLA—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—thyroid cancer	0.000344	0.00377	CbGpPWpGaD
Orlistat—Dizziness—Sorafenib—thyroid cancer	0.000343	0.00178	CcSEcCtD
Orlistat—Abdominal distension—Epirubicin—thyroid cancer	0.000339	0.00176	CcSEcCtD
Orlistat—PNLIP—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	0.000338	0.00371	CbGpPWpGaD
Orlistat—DAGLB—GPCR downstream signaling—CALCA—thyroid cancer	0.000337	0.0037	CbGpPWpGaD
Orlistat—DAGLA—GPCR downstream signaling—CALCA—thyroid cancer	0.000337	0.0037	CbGpPWpGaD
Orlistat—Influenza—Epirubicin—thyroid cancer	0.000337	0.00174	CcSEcCtD
Orlistat—Asthma—Epirubicin—thyroid cancer	0.000337	0.00174	CcSEcCtD
Orlistat—Dry skin—Doxorubicin—thyroid cancer	0.000331	0.00171	CcSEcCtD
Orlistat—Pancreatitis—Epirubicin—thyroid cancer	0.00033	0.00171	CcSEcCtD
Orlistat—DAGLA—Signaling Pathways—TCF7L1—thyroid cancer	0.00033	0.00362	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—TCF7L1—thyroid cancer	0.00033	0.00362	CbGpPWpGaD
Orlistat—Vomiting—Sorafenib—thyroid cancer	0.00033	0.00171	CcSEcCtD
Orlistat—Abdominal pain upper—Doxorubicin—thyroid cancer	0.000329	0.00171	CcSEcCtD
Orlistat—Hypokalaemia—Doxorubicin—thyroid cancer	0.000328	0.0017	CcSEcCtD
Orlistat—Rash—Sorafenib—thyroid cancer	0.000327	0.00169	CcSEcCtD
Orlistat—Dermatitis—Sorafenib—thyroid cancer	0.000327	0.00169	CcSEcCtD
Orlistat—Breast disorder—Doxorubicin—thyroid cancer	0.000326	0.00169	CcSEcCtD
Orlistat—Headache—Sorafenib—thyroid cancer	0.000325	0.00168	CcSEcCtD
Orlistat—FASN—AMPK Signaling—AKT1—thyroid cancer	0.000323	0.00354	CbGpPWpGaD
Orlistat—FASN—SREBP signalling—AKT1—thyroid cancer	0.000323	0.00354	CbGpPWpGaD
Orlistat—Gastritis—Doxorubicin—thyroid cancer	0.000319	0.00165	CcSEcCtD
Orlistat—DAGLB—Signaling by GPCR—SST—thyroid cancer	0.000318	0.00349	CbGpPWpGaD
Orlistat—DAGLA—Signaling by GPCR—SST—thyroid cancer	0.000318	0.00349	CbGpPWpGaD
Orlistat—Abdominal distension—Doxorubicin—thyroid cancer	0.000314	0.00163	CcSEcCtD
Orlistat—Upper respiratory tract infection—Epirubicin—thyroid cancer	0.000313	0.00162	CcSEcCtD
Orlistat—Asthma—Doxorubicin—thyroid cancer	0.000312	0.00161	CcSEcCtD
Orlistat—Influenza—Doxorubicin—thyroid cancer	0.000312	0.00161	CcSEcCtD
Orlistat—Nausea—Sorafenib—thyroid cancer	0.000308	0.00159	CcSEcCtD
Orlistat—DAGLB—Signaling by GPCR—CALCA—thyroid cancer	0.000306	0.00336	CbGpPWpGaD
Orlistat—DAGLA—Signaling by GPCR—CALCA—thyroid cancer	0.000306	0.00336	CbGpPWpGaD
Orlistat—Pancreatitis—Doxorubicin—thyroid cancer	0.000306	0.00158	CcSEcCtD
Orlistat—Infestation NOS—Epirubicin—thyroid cancer	0.0003	0.00156	CcSEcCtD
Orlistat—Infestation—Epirubicin—thyroid cancer	0.0003	0.00156	CcSEcCtD
Orlistat—DAGLB—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—thyroid cancer	0.000296	0.00324	CbGpPWpGaD
Orlistat—DAGLA—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—thyroid cancer	0.000296	0.00324	CbGpPWpGaD
Orlistat—Renal failure—Epirubicin—thyroid cancer	0.000295	0.00153	CcSEcCtD
Orlistat—FASN—Metabolism—HPGD—thyroid cancer	0.000295	0.00323	CbGpPWpGaD
Orlistat—Neuropathy peripheral—Epirubicin—thyroid cancer	0.000295	0.00152	CcSEcCtD
Orlistat—Urinary tract infection—Epirubicin—thyroid cancer	0.000292	0.00151	CcSEcCtD
Orlistat—Upper respiratory tract infection—Doxorubicin—thyroid cancer	0.00029	0.0015	CcSEcCtD
Orlistat—PNLIP—Disease—TPR—thyroid cancer	0.000286	0.00314	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	0.000284	0.00312	CbGpPWpGaD
Orlistat—Hepatobiliary disease—Epirubicin—thyroid cancer	0.000284	0.00147	CcSEcCtD
Orlistat—PLA2G4A—Signaling mediated by p38-alpha and p38-beta—TP53—thyroid cancer	0.000283	0.0031	CbGpPWpGaD
Orlistat—Sinusitis—Epirubicin—thyroid cancer	0.000282	0.00146	CcSEcCtD
Orlistat—PNLIP—Disease—PRKAR1A—thyroid cancer	0.000281	0.00308	CbGpPWpGaD
Orlistat—Infestation—Doxorubicin—thyroid cancer	0.000278	0.00144	CcSEcCtD
Orlistat—Infestation NOS—Doxorubicin—thyroid cancer	0.000278	0.00144	CcSEcCtD
Orlistat—DAGLB—Signaling by GPCR—CDK1—thyroid cancer	0.000277	0.00304	CbGpPWpGaD
Orlistat—DAGLA—Signaling by GPCR—CDK1—thyroid cancer	0.000277	0.00304	CbGpPWpGaD
Orlistat—PLA2G4A—p38 MAPK Signaling Pathway—HRAS—thyroid cancer	0.000277	0.00303	CbGpPWpGaD
Orlistat—FASN—Disease—TCF7L1—thyroid cancer	0.000276	0.00303	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—TCF7L1—thyroid cancer	0.000274	0.003	CbGpPWpGaD
Orlistat—Renal failure—Doxorubicin—thyroid cancer	0.000273	0.00141	CcSEcCtD
Orlistat—Neuropathy peripheral—Doxorubicin—thyroid cancer	0.000273	0.00141	CcSEcCtD
Orlistat—Haemoglobin—Epirubicin—thyroid cancer	0.000271	0.0014	CcSEcCtD
Orlistat—Urinary tract infection—Doxorubicin—thyroid cancer	0.00027	0.0014	CcSEcCtD
Orlistat—Hepatitis—Epirubicin—thyroid cancer	0.00027	0.0014	CcSEcCtD
Orlistat—Haemorrhage—Epirubicin—thyroid cancer	0.00027	0.0014	CcSEcCtD
Orlistat—PNLIP—Disease—MEN1—thyroid cancer	0.000269	0.00295	CbGpPWpGaD
Orlistat—Pharyngitis—Epirubicin—thyroid cancer	0.000268	0.00139	CcSEcCtD
Orlistat—Urinary tract disorder—Epirubicin—thyroid cancer	0.000266	0.00138	CcSEcCtD
Orlistat—Oedema peripheral—Epirubicin—thyroid cancer	0.000266	0.00138	CcSEcCtD
Orlistat—Urethral disorder—Epirubicin—thyroid cancer	0.000264	0.00137	CcSEcCtD
Orlistat—Hepatobiliary disease—Doxorubicin—thyroid cancer	0.000263	0.00136	CcSEcCtD
Orlistat—Sinusitis—Doxorubicin—thyroid cancer	0.000261	0.00135	CcSEcCtD
Orlistat—DAGLA—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—thyroid cancer	0.000251	0.00276	CbGpPWpGaD
Orlistat—DAGLB—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—thyroid cancer	0.000251	0.00276	CbGpPWpGaD
Orlistat—Haemoglobin—Doxorubicin—thyroid cancer	0.000251	0.0013	CcSEcCtD
Orlistat—Hepatitis—Doxorubicin—thyroid cancer	0.00025	0.00129	CcSEcCtD
Orlistat—Haemorrhage—Doxorubicin—thyroid cancer	0.00025	0.00129	CcSEcCtD
Orlistat—PLA2G4A—PDGF Pathway—HRAS—thyroid cancer	0.000248	0.00272	CbGpPWpGaD
Orlistat—Pharyngitis—Doxorubicin—thyroid cancer	0.000248	0.00128	CcSEcCtD
Orlistat—Urinary tract disorder—Doxorubicin—thyroid cancer	0.000246	0.00128	CcSEcCtD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—RXRA—thyroid cancer	0.000246	0.0027	CbGpPWpGaD
Orlistat—Oedema peripheral—Doxorubicin—thyroid cancer	0.000246	0.00127	CcSEcCtD
Orlistat—Urethral disorder—Doxorubicin—thyroid cancer	0.000245	0.00127	CcSEcCtD
Orlistat—Immune system disorder—Epirubicin—thyroid cancer	0.000244	0.00126	CcSEcCtD
Orlistat—Mediastinal disorder—Epirubicin—thyroid cancer	0.000243	0.00126	CcSEcCtD
Orlistat—DAGLA—Signaling Pathways—TSHR—thyroid cancer	0.000242	0.00265	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—TSHR—thyroid cancer	0.000242	0.00265	CbGpPWpGaD
Orlistat—CYP3A4—Constitutive Androstane Receptor Pathway—RXRA—thyroid cancer	0.00024	0.00264	CbGpPWpGaD
Orlistat—PNLIP—Metabolism—TPR—thyroid cancer	0.000239	0.00263	CbGpPWpGaD
Orlistat—FASN—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	0.000239	0.00262	CbGpPWpGaD
Orlistat—Alopecia—Epirubicin—thyroid cancer	0.000238	0.00123	CcSEcCtD
Orlistat—DAGLA—Signaling Pathways—PRKAR1A—thyroid cancer	0.000238	0.00261	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—PRKAR1A—thyroid cancer	0.000238	0.00261	CbGpPWpGaD
Orlistat—Mental disorder—Epirubicin—thyroid cancer	0.000236	0.00122	CcSEcCtD
Orlistat—PNLIP—Metabolism—PRKAR1A—thyroid cancer	0.000236	0.00258	CbGpPWpGaD
Orlistat—Malnutrition—Epirubicin—thyroid cancer	0.000235	0.00122	CcSEcCtD
Orlistat—Flatulence—Epirubicin—thyroid cancer	0.000231	0.0012	CcSEcCtD
Orlistat—Dysgeusia—Epirubicin—thyroid cancer	0.00023	0.00119	CcSEcCtD
Orlistat—DAGLA—Signaling Pathways—MEN1—thyroid cancer	0.000227	0.00249	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—MEN1—thyroid cancer	0.000227	0.00249	CbGpPWpGaD
Orlistat—Back pain—Epirubicin—thyroid cancer	0.000227	0.00118	CcSEcCtD
Orlistat—Muscle spasms—Epirubicin—thyroid cancer	0.000226	0.00117	CcSEcCtD
Orlistat—Immune system disorder—Doxorubicin—thyroid cancer	0.000225	0.00117	CcSEcCtD
Orlistat—Mediastinal disorder—Doxorubicin—thyroid cancer	0.000225	0.00116	CcSEcCtD
Orlistat—PLA2G4A—Signaling by GPCR—CALCB—thyroid cancer	0.000222	0.00244	CbGpPWpGaD
Orlistat—Vision blurred—Epirubicin—thyroid cancer	0.000221	0.00115	CcSEcCtD
Orlistat—Alopecia—Doxorubicin—thyroid cancer	0.000221	0.00114	CcSEcCtD
Orlistat—Mental disorder—Doxorubicin—thyroid cancer	0.000219	0.00113	CcSEcCtD
Orlistat—Ill-defined disorder—Epirubicin—thyroid cancer	0.000218	0.00113	CcSEcCtD
Orlistat—Malnutrition—Doxorubicin—thyroid cancer	0.000217	0.00112	CcSEcCtD
Orlistat—DAGLB—Platelet activation, signaling and aggregation—AKT1—thyroid cancer	0.000217	0.00238	CbGpPWpGaD
Orlistat—DAGLA—Platelet activation, signaling and aggregation—AKT1—thyroid cancer	0.000217	0.00238	CbGpPWpGaD
Orlistat—Flatulence—Doxorubicin—thyroid cancer	0.000214	0.00111	CcSEcCtD
Orlistat—PNLIP—Disease—CALCA—thyroid cancer	0.000214	0.00235	CbGpPWpGaD
Orlistat—PNLIP—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	0.000214	0.00234	CbGpPWpGaD
Orlistat—Dysgeusia—Doxorubicin—thyroid cancer	0.000213	0.0011	CcSEcCtD
Orlistat—PLA2G4A—PDGFR-beta signaling pathway—BRAF—thyroid cancer	0.000212	0.00233	CbGpPWpGaD
Orlistat—CYP3A4—Metapathway biotransformation—CHST14—thyroid cancer	0.000212	0.00233	CbGpPWpGaD
Orlistat—Malaise—Epirubicin—thyroid cancer	0.000212	0.0011	CcSEcCtD
Orlistat—Vertigo—Epirubicin—thyroid cancer	0.000211	0.00109	CcSEcCtD
Orlistat—Back pain—Doxorubicin—thyroid cancer	0.00021	0.00109	CcSEcCtD
Orlistat—Muscle spasms—Doxorubicin—thyroid cancer	0.000209	0.00108	CcSEcCtD
Orlistat—Palpitations—Epirubicin—thyroid cancer	0.000207	0.00107	CcSEcCtD
Orlistat—DAGLB—Signaling Pathways—PTCH1—thyroid cancer	0.000205	0.00225	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—PTCH1—thyroid cancer	0.000205	0.00225	CbGpPWpGaD
Orlistat—Cough—Epirubicin—thyroid cancer	0.000205	0.00106	CcSEcCtD
Orlistat—Vision blurred—Doxorubicin—thyroid cancer	0.000205	0.00106	CcSEcCtD
Orlistat—Convulsion—Epirubicin—thyroid cancer	0.000203	0.00105	CcSEcCtD
Orlistat—FASN—Disease—TPR—thyroid cancer	0.000202	0.00222	CbGpPWpGaD
Orlistat—Ill-defined disorder—Doxorubicin—thyroid cancer	0.000202	0.00104	CcSEcCtD
Orlistat—PNLIP—Signaling Pathways—TSHR—thyroid cancer	0.0002	0.0022	CbGpPWpGaD
Orlistat—Myalgia—Epirubicin—thyroid cancer	0.0002	0.00104	CcSEcCtD
Orlistat—Chest pain—Epirubicin—thyroid cancer	0.0002	0.00104	CcSEcCtD
Orlistat—Anxiety—Epirubicin—thyroid cancer	0.000199	0.00103	CcSEcCtD
Orlistat—FASN—Disease—PRKAR1A—thyroid cancer	0.000199	0.00218	CbGpPWpGaD
Orlistat—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—thyroid cancer	0.000199	0.00103	CcSEcCtD
Orlistat—Discomfort—Epirubicin—thyroid cancer	0.000198	0.00102	CcSEcCtD
Orlistat—PNLIP—Signaling Pathways—PRKAR1A—thyroid cancer	0.000197	0.00216	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—MINPP1—thyroid cancer	0.000196	0.00215	CbGpPWpGaD
Orlistat—Malaise—Doxorubicin—thyroid cancer	0.000196	0.00101	CcSEcCtD
Orlistat—Dry mouth—Epirubicin—thyroid cancer	0.000196	0.00101	CcSEcCtD
Orlistat—Vertigo—Doxorubicin—thyroid cancer	0.000195	0.00101	CcSEcCtD
Orlistat—PNLIP—Disease—CDK1—thyroid cancer	0.000194	0.00212	CbGpPWpGaD
Orlistat—Palpitations—Doxorubicin—thyroid cancer	0.000192	0.000994	CcSEcCtD
Orlistat—Anaphylactic shock—Epirubicin—thyroid cancer	0.000192	0.000992	CcSEcCtD
Orlistat—Oedema—Epirubicin—thyroid cancer	0.000192	0.000992	CcSEcCtD
Orlistat—Infection—Epirubicin—thyroid cancer	0.00019	0.000986	CcSEcCtD
Orlistat—FASN—Disease—MEN1—thyroid cancer	0.00019	0.00209	CbGpPWpGaD
Orlistat—Cough—Doxorubicin—thyroid cancer	0.00019	0.000982	CcSEcCtD
Orlistat—PNLIP—Signaling Pathways—MEN1—thyroid cancer	0.000188	0.00206	CbGpPWpGaD
Orlistat—Convulsion—Doxorubicin—thyroid cancer	0.000188	0.000975	CcSEcCtD
Orlistat—DAGLB—Signaling Pathways—SST—thyroid cancer	0.000188	0.00206	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—SST—thyroid cancer	0.000188	0.00206	CbGpPWpGaD
Orlistat—Nervous system disorder—Epirubicin—thyroid cancer	0.000188	0.000973	CcSEcCtD
Orlistat—Skin disorder—Epirubicin—thyroid cancer	0.000186	0.000964	CcSEcCtD
Orlistat—Hyperhidrosis—Epirubicin—thyroid cancer	0.000185	0.000959	CcSEcCtD
Orlistat—Chest pain—Doxorubicin—thyroid cancer	0.000185	0.000958	CcSEcCtD
Orlistat—Myalgia—Doxorubicin—thyroid cancer	0.000185	0.000958	CcSEcCtD
Orlistat—Anxiety—Doxorubicin—thyroid cancer	0.000184	0.000954	CcSEcCtD
Orlistat—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—thyroid cancer	0.000184	0.000951	CcSEcCtD
Orlistat—Discomfort—Doxorubicin—thyroid cancer	0.000183	0.000946	CcSEcCtD
Orlistat—DAGLA—Signaling Pathways—CALCA—thyroid cancer	0.000181	0.00198	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—CALCA—thyroid cancer	0.000181	0.00198	CbGpPWpGaD
Orlistat—Dry mouth—Doxorubicin—thyroid cancer	0.000181	0.000937	CcSEcCtD
Orlistat—PNLIP—Metabolism—SLC5A5—thyroid cancer	0.000179	0.00197	CbGpPWpGaD
Orlistat—Anaphylactic shock—Doxorubicin—thyroid cancer	0.000177	0.000918	CcSEcCtD
Orlistat—Oedema—Doxorubicin—thyroid cancer	0.000177	0.000918	CcSEcCtD
Orlistat—PLA2G4A—Hemostasis—PRKAR1A—thyroid cancer	0.000176	0.00193	CbGpPWpGaD
Orlistat—Infection—Doxorubicin—thyroid cancer	0.000176	0.000912	CcSEcCtD
Orlistat—Musculoskeletal discomfort—Epirubicin—thyroid cancer	0.000175	0.000904	CcSEcCtD
Orlistat—Nervous system disorder—Doxorubicin—thyroid cancer	0.000174	0.0009	CcSEcCtD
Orlistat—Insomnia—Epirubicin—thyroid cancer	0.000173	0.000897	CcSEcCtD
Orlistat—DAGLB—Hemostasis—NRAS—thyroid cancer	0.000173	0.0019	CbGpPWpGaD
Orlistat—DAGLA—Hemostasis—NRAS—thyroid cancer	0.000173	0.0019	CbGpPWpGaD
Orlistat—PLA2G4A—Fc-epsilon receptor I signaling in mast cells—HRAS—thyroid cancer	0.000173	0.0019	CbGpPWpGaD
Orlistat—Skin disorder—Doxorubicin—thyroid cancer	0.000172	0.000892	CcSEcCtD
Orlistat—Paraesthesia—Epirubicin—thyroid cancer	0.000172	0.000891	CcSEcCtD
Orlistat—Hyperhidrosis—Doxorubicin—thyroid cancer	0.000171	0.000888	CcSEcCtD
Orlistat—PNLIP—Signaling Pathways—PTCH1—thyroid cancer	0.00017	0.00187	CbGpPWpGaD
Orlistat—FASN—Metabolism—TPR—thyroid cancer	0.000169	0.00186	CbGpPWpGaD
Orlistat—PLA2G4A—Endothelins—HRAS—thyroid cancer	0.000169	0.00185	CbGpPWpGaD
Orlistat—Dyspepsia—Epirubicin—thyroid cancer	0.000169	0.000873	CcSEcCtD
Orlistat—PNLIP—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	0.000168	0.00184	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—NDUFA13—thyroid cancer	0.000167	0.00183	CbGpPWpGaD
Orlistat—FASN—Metabolism—PRKAR1A—thyroid cancer	0.000167	0.00183	CbGpPWpGaD
Orlistat—Decreased appetite—Epirubicin—thyroid cancer	0.000167	0.000863	CcSEcCtD
Orlistat—Gastrointestinal disorder—Epirubicin—thyroid cancer	0.000165	0.000857	CcSEcCtD
Orlistat—Fatigue—Epirubicin—thyroid cancer	0.000165	0.000855	CcSEcCtD
Orlistat—Pain—Epirubicin—thyroid cancer	0.000164	0.000848	CcSEcCtD
Orlistat—DAGLA—Signaling Pathways—CDK1—thyroid cancer	0.000164	0.0018	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—CDK1—thyroid cancer	0.000164	0.0018	CbGpPWpGaD
Orlistat—Musculoskeletal discomfort—Doxorubicin—thyroid cancer	0.000162	0.000836	CcSEcCtD
Orlistat—Insomnia—Doxorubicin—thyroid cancer	0.00016	0.00083	CcSEcCtD
Orlistat—Paraesthesia—Doxorubicin—thyroid cancer	0.000159	0.000824	CcSEcCtD
Orlistat—Feeling abnormal—Epirubicin—thyroid cancer	0.000158	0.000818	CcSEcCtD
Orlistat—PLA2G4A—Metabolism—CHST14—thyroid cancer	0.000157	0.00172	CbGpPWpGaD
Orlistat—Gastrointestinal pain—Epirubicin—thyroid cancer	0.000157	0.000811	CcSEcCtD
Orlistat—Dyspepsia—Doxorubicin—thyroid cancer	0.000156	0.000808	CcSEcCtD
Orlistat—PNLIP—Signaling Pathways—SST—thyroid cancer	0.000156	0.00171	CbGpPWpGaD
Orlistat—PNLIP—Disease—NRG1—thyroid cancer	0.000156	0.00171	CbGpPWpGaD
Orlistat—Decreased appetite—Doxorubicin—thyroid cancer	0.000154	0.000798	CcSEcCtD
Orlistat—Gastrointestinal disorder—Doxorubicin—thyroid cancer	0.000153	0.000793	CcSEcCtD
Orlistat—PLA2G4A—Fc-epsilon receptor I signaling in mast cells—AKT1—thyroid cancer	0.000153	0.00168	CbGpPWpGaD
Orlistat—Fatigue—Doxorubicin—thyroid cancer	0.000153	0.000792	CcSEcCtD
Orlistat—Urticaria—Epirubicin—thyroid cancer	0.000152	0.000788	CcSEcCtD
Orlistat—Pain—Doxorubicin—thyroid cancer	0.000152	0.000785	CcSEcCtD
Orlistat—Body temperature increased—Epirubicin—thyroid cancer	0.000151	0.000784	CcSEcCtD
Orlistat—Abdominal pain—Epirubicin—thyroid cancer	0.000151	0.000784	CcSEcCtD
Orlistat—FASN—Disease—CALCA—thyroid cancer	0.000151	0.00166	CbGpPWpGaD
Orlistat—FASN—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	0.000151	0.00166	CbGpPWpGaD
Orlistat—PNLIP—Metabolism—RXRA—thyroid cancer	0.000151	0.00165	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—CALCA—thyroid cancer	0.00015	0.00164	CbGpPWpGaD
Orlistat—PLA2G4A—PDGFR-beta signaling pathway—PTEN—thyroid cancer	0.00015	0.00164	CbGpPWpGaD
Orlistat—DAGLB—Hemostasis—KRAS—thyroid cancer	0.000149	0.00164	CbGpPWpGaD
Orlistat—DAGLA—Hemostasis—KRAS—thyroid cancer	0.000149	0.00164	CbGpPWpGaD
Orlistat—PLA2G4A—Endothelins—AKT1—thyroid cancer	0.000149	0.00163	CbGpPWpGaD
Orlistat—PNLIP—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	0.000146	0.00161	CbGpPWpGaD
Orlistat—Feeling abnormal—Doxorubicin—thyroid cancer	0.000146	0.000757	CcSEcCtD
Orlistat—CYP3A4—Cytochrome P450 - arranged by substrate type—RXRA—thyroid cancer	0.000145	0.00159	CbGpPWpGaD
Orlistat—Gastrointestinal pain—Doxorubicin—thyroid cancer	0.000145	0.000751	CcSEcCtD
Orlistat—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—thyroid cancer	0.000145	0.00159	CbGpPWpGaD
Orlistat—PLA2G4A—AGE/RAGE pathway—AKT1—thyroid cancer	0.000144	0.00157	CbGpPWpGaD
Orlistat—Hypersensitivity—Epirubicin—thyroid cancer	0.000141	0.000731	CcSEcCtD
Orlistat—Urticaria—Doxorubicin—thyroid cancer	0.000141	0.000729	CcSEcCtD
Orlistat—Abdominal pain—Doxorubicin—thyroid cancer	0.00014	0.000726	CcSEcCtD
Orlistat—Body temperature increased—Doxorubicin—thyroid cancer	0.00014	0.000726	CcSEcCtD
Orlistat—PNLIP—Disease—TERT—thyroid cancer	0.00014	0.00153	CbGpPWpGaD
Orlistat—PLA2G4A—Phospholipid metabolism—PTEN—thyroid cancer	0.000138	0.00151	CbGpPWpGaD
Orlistat—Asthenia—Epirubicin—thyroid cancer	0.000137	0.000712	CcSEcCtD
Orlistat—FASN—Disease—CDK1—thyroid cancer	0.000137	0.0015	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—CDK1—thyroid cancer	0.000136	0.00149	CbGpPWpGaD
Orlistat—Pruritus—Epirubicin—thyroid cancer	0.000136	0.000702	CcSEcCtD
Orlistat—PNLIP—Disease—HIF1A—thyroid cancer	0.000134	0.00146	CbGpPWpGaD
Orlistat—PLA2G4A—PDGFR-beta signaling pathway—NRAS—thyroid cancer	0.000133	0.00146	CbGpPWpGaD
Orlistat—DAGLA—Hemostasis—TP53—thyroid cancer	0.000133	0.00145	CbGpPWpGaD
Orlistat—DAGLB—Hemostasis—TP53—thyroid cancer	0.000133	0.00145	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—NRG1—thyroid cancer	0.000131	0.00144	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—NRG1—thyroid cancer	0.000131	0.00144	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—CALCB—thyroid cancer	0.000131	0.00144	CbGpPWpGaD
Orlistat—Diarrhoea—Epirubicin—thyroid cancer	0.000131	0.000679	CcSEcCtD
Orlistat—Hypersensitivity—Doxorubicin—thyroid cancer	0.000131	0.000676	CcSEcCtD
Orlistat—Asthenia—Doxorubicin—thyroid cancer	0.000127	0.000659	CcSEcCtD
Orlistat—FASN—Metabolism—SLC5A5—thyroid cancer	0.000127	0.00139	CbGpPWpGaD
Orlistat—DAGLA—Hemostasis—HRAS—thyroid cancer	0.000127	0.00139	CbGpPWpGaD
Orlistat—DAGLB—Hemostasis—HRAS—thyroid cancer	0.000127	0.00139	CbGpPWpGaD
Orlistat—Dizziness—Epirubicin—thyroid cancer	0.000127	0.000656	CcSEcCtD
Orlistat—PLA2G4A—Metabolism—HPGD—thyroid cancer	0.000127	0.00139	CbGpPWpGaD
Orlistat—Pruritus—Doxorubicin—thyroid cancer	0.000125	0.00065	CcSEcCtD
Orlistat—PLA2G4A—Signaling Pathways—TRIM33—thyroid cancer	0.000124	0.00137	CbGpPWpGaD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—PTGS2—thyroid cancer	0.000122	0.00134	CbGpPWpGaD
Orlistat—Vomiting—Epirubicin—thyroid cancer	0.000122	0.000631	CcSEcCtD
Orlistat—Diarrhoea—Doxorubicin—thyroid cancer	0.000121	0.000628	CcSEcCtD
Orlistat—Rash—Epirubicin—thyroid cancer	0.000121	0.000626	CcSEcCtD
Orlistat—Dermatitis—Epirubicin—thyroid cancer	0.000121	0.000625	CcSEcCtD
Orlistat—Headache—Epirubicin—thyroid cancer	0.00012	0.000622	CcSEcCtD
Orlistat—FASN—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	0.000119	0.0013	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—TERT—thyroid cancer	0.000118	0.00129	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—TERT—thyroid cancer	0.000118	0.00129	CbGpPWpGaD
Orlistat—CYP3A4—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	0.000118	0.00129	CbGpPWpGaD
Orlistat—Dizziness—Doxorubicin—thyroid cancer	0.000117	0.000607	CcSEcCtD
Orlistat—PLA2G4A—Hemostasis—IFNA2—thyroid cancer	0.000117	0.00128	CbGpPWpGaD
Orlistat—PLA2G4A—PDGFR-beta signaling pathway—KRAS—thyroid cancer	0.000115	0.00126	CbGpPWpGaD
Orlistat—Nausea—Epirubicin—thyroid cancer	0.000114	0.000589	CcSEcCtD
Orlistat—DAGLB—Signaling Pathways—HIF1A—thyroid cancer	0.000113	0.00124	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—HIF1A—thyroid cancer	0.000113	0.00124	CbGpPWpGaD
Orlistat—Vomiting—Doxorubicin—thyroid cancer	0.000113	0.000584	CcSEcCtD
Orlistat—DAGLB—Hemostasis—AKT1—thyroid cancer	0.000112	0.00123	CbGpPWpGaD
Orlistat—DAGLA—Hemostasis—AKT1—thyroid cancer	0.000112	0.00123	CbGpPWpGaD
Orlistat—Rash—Doxorubicin—thyroid cancer	0.000112	0.000579	CcSEcCtD
Orlistat—Dermatitis—Doxorubicin—thyroid cancer	0.000112	0.000578	CcSEcCtD
Orlistat—Headache—Doxorubicin—thyroid cancer	0.000111	0.000575	CcSEcCtD
Orlistat—PNLIP—Disease—BRAF—thyroid cancer	0.000111	0.00121	CbGpPWpGaD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—CCND1—thyroid cancer	0.00011	0.00121	CbGpPWpGaD
Orlistat—FASN—Disease—NRG1—thyroid cancer	0.00011	0.00121	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—NRG1—thyroid cancer	0.000109	0.00119	CbGpPWpGaD
Orlistat—FASN—Metabolism—RXRA—thyroid cancer	0.000107	0.00117	CbGpPWpGaD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—PTEN—thyroid cancer	0.000107	0.00117	CbGpPWpGaD
Orlistat—Nausea—Doxorubicin—thyroid cancer	0.000105	0.000545	CcSEcCtD
Orlistat—FASN—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	0.000104	0.00114	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—TSHR—thyroid cancer	0.000103	0.00113	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	0.000103	0.00113	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—PRKAR1A—thyroid cancer	0.000101	0.00111	CbGpPWpGaD
Orlistat—DAGLB—Signaling by GPCR—NRAS—thyroid cancer	9.94e-05	0.00109	CbGpPWpGaD
Orlistat—DAGLA—Signaling by GPCR—NRAS—thyroid cancer	9.94e-05	0.00109	CbGpPWpGaD
Orlistat—FASN—Disease—TERT—thyroid cancer	9.88e-05	0.00108	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—TERT—thyroid cancer	9.78e-05	0.00107	CbGpPWpGaD
Orlistat—PLA2G4A—PDGFR-beta signaling pathway—HRAS—thyroid cancer	9.76e-05	0.00107	CbGpPWpGaD
Orlistat—PNLIP—Metabolism—PPARG—thyroid cancer	9.51e-05	0.00104	CbGpPWpGaD
Orlistat—FASN—Disease—HIF1A—thyroid cancer	9.45e-05	0.00104	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—HIF1A—thyroid cancer	9.35e-05	0.00103	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—BRAF—thyroid cancer	9.35e-05	0.00102	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—BRAF—thyroid cancer	9.35e-05	0.00102	CbGpPWpGaD
Orlistat—PNLIP—Disease—PTGS2—thyroid cancer	8.93e-05	0.00098	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—PTCH1—thyroid cancer	8.75e-05	0.00096	CbGpPWpGaD
Orlistat—DAGLA—Signaling by GPCR—KRAS—thyroid cancer	8.56e-05	0.000938	CbGpPWpGaD
Orlistat—DAGLB—Signaling by GPCR—KRAS—thyroid cancer	8.56e-05	0.000938	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—TCF7L1—thyroid cancer	8.31e-05	0.000911	CbGpPWpGaD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—KRAS—thyroid cancer	8.18e-05	0.000897	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—SST—thyroid cancer	8e-05	0.000878	CbGpPWpGaD
Orlistat—FASN—Disease—BRAF—thyroid cancer	7.82e-05	0.000858	CbGpPWpGaD
Orlistat—PNLIP—Disease—PTEN—thyroid cancer	7.79e-05	0.000854	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—BRAF—thyroid cancer	7.74e-05	0.000849	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—CALCA—thyroid cancer	7.7e-05	0.000845	CbGpPWpGaD
Orlistat—PNLIP—Metabolism—PTGS2—thyroid cancer	7.48e-05	0.00082	CbGpPWpGaD
Orlistat—DAGLB—Signaling by GPCR—HRAS—thyroid cancer	7.27e-05	0.000798	CbGpPWpGaD
Orlistat—DAGLA—Signaling by GPCR—HRAS—thyroid cancer	7.27e-05	0.000798	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—TPR—thyroid cancer	7.27e-05	0.000797	CbGpPWpGaD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—TP53—thyroid cancer	7.27e-05	0.000797	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—PRKAR1A—thyroid cancer	7.15e-05	0.000784	CbGpPWpGaD
Orlistat—DAGLB—GPCR downstream signaling—AKT1—thyroid cancer	7.07e-05	0.000776	CbGpPWpGaD
Orlistat—DAGLA—GPCR downstream signaling—AKT1—thyroid cancer	7.07e-05	0.000776	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—CDK1—thyroid cancer	6.97e-05	0.000765	CbGpPWpGaD
Orlistat—PNLIP—Disease—NRAS—thyroid cancer	6.95e-05	0.000762	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—CCND1—thyroid cancer	6.82e-05	0.000748	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—CCND1—thyroid cancer	6.82e-05	0.000748	CbGpPWpGaD
Orlistat—FASN—Metabolism—PPARG—thyroid cancer	6.73e-05	0.000738	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—PTEN—thyroid cancer	6.58e-05	0.000722	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—PTEN—thyroid cancer	6.58e-05	0.000722	CbGpPWpGaD
Orlistat—PNLIP—Metabolism—PTEN—thyroid cancer	6.52e-05	0.000715	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	6.48e-05	0.000711	CbGpPWpGaD
Orlistat—DAGLA—Signaling by GPCR—AKT1—thyroid cancer	6.42e-05	0.000704	CbGpPWpGaD
Orlistat—DAGLB—Signaling by GPCR—AKT1—thyroid cancer	6.42e-05	0.000704	CbGpPWpGaD
Orlistat—FASN—Disease—PTGS2—thyroid cancer	6.32e-05	0.000693	CbGpPWpGaD
Orlistat—CYP3A4—Biological oxidations—RXRA—thyroid cancer	6.26e-05	0.000687	CbGpPWpGaD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—AKT1—thyroid cancer	6.14e-05	0.000673	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—TSHR—thyroid cancer	6.08e-05	0.000667	CbGpPWpGaD
Orlistat—PNLIP—Disease—KRAS—thyroid cancer	5.98e-05	0.000656	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—PRKAR1A—thyroid cancer	5.98e-05	0.000656	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—NRAS—thyroid cancer	5.87e-05	0.000644	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—NRAS—thyroid cancer	5.87e-05	0.000644	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—MEN1—thyroid cancer	5.72e-05	0.000627	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—CCND1—thyroid cancer	5.65e-05	0.00062	CbGpPWpGaD
Orlistat—FASN—Disease—PTEN—thyroid cancer	5.51e-05	0.000604	CbGpPWpGaD
Orlistat—PLA2G4A—Platelet activation, signaling and aggregation—AKT1—thyroid cancer	5.46e-05	0.000599	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—PTEN—thyroid cancer	5.46e-05	0.000598	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—SLC5A5—thyroid cancer	5.44e-05	0.000597	CbGpPWpGaD
Orlistat—FASN—Metabolism—PTGS2—thyroid cancer	5.29e-05	0.00058	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—PTCH1—thyroid cancer	5.17e-05	0.000567	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	5.1e-05	0.000559	CbGpPWpGaD
Orlistat—PNLIP—Disease—HRAS—thyroid cancer	5.08e-05	0.000558	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—KRAS—thyroid cancer	5.06e-05	0.000554	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—KRAS—thyroid cancer	5.06e-05	0.000554	CbGpPWpGaD
Orlistat—FASN—Disease—NRAS—thyroid cancer	4.92e-05	0.000539	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—NRAS—thyroid cancer	4.87e-05	0.000534	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—SST—thyroid cancer	4.73e-05	0.000518	CbGpPWpGaD
Orlistat—FASN—Metabolism—PTEN—thyroid cancer	4.62e-05	0.000506	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—MINPP1—thyroid cancer	4.6e-05	0.000504	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—RXRA—thyroid cancer	4.57e-05	0.000501	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—CALCA—thyroid cancer	4.55e-05	0.000499	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—TP53—thyroid cancer	4.49e-05	0.000493	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—TP53—thyroid cancer	4.49e-05	0.000493	CbGpPWpGaD
Orlistat—PNLIP—Disease—AKT1—thyroid cancer	4.49e-05	0.000492	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	4.45e-05	0.000488	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—NRAS—thyroid cancer	4.36e-05	0.000478	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—HRAS—thyroid cancer	4.3e-05	0.000471	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—HRAS—thyroid cancer	4.3e-05	0.000471	CbGpPWpGaD
Orlistat—FASN—Disease—KRAS—thyroid cancer	4.23e-05	0.000464	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—KRAS—thyroid cancer	4.19e-05	0.000459	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—CDK1—thyroid cancer	4.12e-05	0.000452	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—NDUFA13—thyroid cancer	3.91e-05	0.000429	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—AKT1—thyroid cancer	3.79e-05	0.000416	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—AKT1—thyroid cancer	3.79e-05	0.000416	CbGpPWpGaD
Orlistat—PNLIP—Metabolism—AKT1—thyroid cancer	3.76e-05	0.000412	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—KRAS—thyroid cancer	3.75e-05	0.000411	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—TP53—thyroid cancer	3.72e-05	0.000408	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—CHST14—thyroid cancer	3.68e-05	0.000403	CbGpPWpGaD
Orlistat—FASN—Disease—HRAS—thyroid cancer	3.6e-05	0.000394	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—HRAS—thyroid cancer	3.56e-05	0.00039	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—TP53—thyroid cancer	3.33e-05	0.000366	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—NRG1—thyroid cancer	3.31e-05	0.000363	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—HRAS—thyroid cancer	3.19e-05	0.00035	CbGpPWpGaD
Orlistat—FASN—Disease—AKT1—thyroid cancer	3.18e-05	0.000348	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—AKT1—thyroid cancer	3.14e-05	0.000345	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—TERT—thyroid cancer	2.97e-05	0.000326	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—HPGD—thyroid cancer	2.96e-05	0.000325	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—PPARG—thyroid cancer	2.89e-05	0.000317	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—HIF1A—thyroid cancer	2.84e-05	0.000311	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—AKT1—thyroid cancer	2.82e-05	0.000309	CbGpPWpGaD
Orlistat—FASN—Metabolism—AKT1—thyroid cancer	2.66e-05	0.000292	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—NRAS—thyroid cancer	2.5e-05	0.000274	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—BRAF—thyroid cancer	2.35e-05	0.000258	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—PTGS2—thyroid cancer	2.27e-05	0.000249	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—KRAS—thyroid cancer	2.15e-05	0.000236	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—PTEN—thyroid cancer	1.98e-05	0.000217	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—HRAS—thyroid cancer	1.83e-05	0.000201	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—CCND1—thyroid cancer	1.72e-05	0.000188	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—TPR—thyroid cancer	1.7e-05	0.000187	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—PRKAR1A—thyroid cancer	1.68e-05	0.000184	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—PTEN—thyroid cancer	1.66e-05	0.000182	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—AKT1—thyroid cancer	1.62e-05	0.000177	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—NRAS—thyroid cancer	1.48e-05	0.000162	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—SLC5A5—thyroid cancer	1.27e-05	0.00014	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—KRAS—thyroid cancer	1.27e-05	0.000139	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—AKT1—thyroid cancer	1.14e-05	0.000125	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—TP53—thyroid cancer	1.13e-05	0.000124	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—HRAS—thyroid cancer	1.08e-05	0.000119	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—RXRA—thyroid cancer	1.07e-05	0.000117	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—AKT1—thyroid cancer	9.55e-06	0.000105	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—PPARG—thyroid cancer	6.76e-06	7.41e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—PTGS2—thyroid cancer	5.32e-06	5.83e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—PTEN—thyroid cancer	4.64e-06	5.09e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—AKT1—thyroid cancer	2.67e-06	2.93e-05	CbGpPWpGaD
